NCT00101452View on ClinicalTrials.gov

Safety and Effectiveness of S-adenosyl-l-methionine (SAMe) for the Treatment of Major Depression

NACompletedINTERVENTIONAL
Enrollment

199

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Depression
Interventions
DRUG

S-adenosyl-l-methionine

1600 mg per day with possibility of increasing to 3200 mg per day at 6 weeks

DRUG

Escitalopram

10 mg per day, with possibility of increasing to 20 mg/day at 6 weeks

DRUG

Placebo

placebo capsules look like escitalopram capsules and SAMe capsules

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02906

Butler Hospital, Providence

All Listed Sponsors
collaborator

National Center for Complementary and Integrative Health (NCCIH)

NIH

lead

Maurizio Fava, MD

OTHER

NCT00101452 - Safety and Effectiveness of S-adenosyl-l-methionine (SAMe) for the Treatment of Major Depression | Biotech Hunter | Biotech Hunter